Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R. Westin, Frederick L. Locke, Olalekan O. Oluwole et al.|New England Journal of Medicine|2023Cited by 437
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Nirali N. Shah, Dina Schneider et al.|Blood|2022Cited by 179
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Nirali N. Shah, Bonnie Yates et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 35
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemiaGeorge Mo, Nirali N. Shah, Hao‐Wei Wang et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 31
Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALLHaneen Shalabi, Nirali N. Shah, Bonnie Yates et al.|Cancer Research|2020Cited by 8